Introduction
Repair of carotid stenosis in additional to best medical therapy (BMT) is currently the best way to treat most asymptomatic patients with 60e99% carotid stenosis. Carotid stenosis causes preventable strokes. The unfortunates who present with stroke due to carotid stenosis (and their even more unfortunate counterparts who experienced a fatal stroke as the first sign of trouble) all harboured an asymptomatic lesion prior to their respective events. Carotid repair used judiciously in concert with BMT and performed well, can have life-long protective effects against stroke-related death and disability for patients with asymptomatic carotid stenosis. 1e3 There is a difference between critical analysis and being unreasonably critical. Reckless claims have been made about the superiority of BMT alone for 60e99% carotid stenosis. 4e7 Small patient cohorts including minor lesions with limited follow up have done 'well' with BMT alone and that has been used to advocate the cessation of carotid repair. 8e13 Practitioners have been accused of self enrichment as the motivation for carotid repair. 14 We are proudly informed that in the UK, only 20% of patients undergoing CEA are being treated for asymptomatic carotid stenosis, while many times that number who could benefit from repair will go on to have preventable stroke. 14, 15 This leads to the following points.
1) Each time repair plus BMT has been compared to BMT alone, repair has had significant and lasting benefits. 1e3 There are numerous current organizational guidelines recommending repair and detailing the benefits (Table 1 ). 16e19 2) Anyone who believes that they are performing carotid repair for their own benefit and not for the benefit of the patient should stop doing it immediately. 14 3) BMT has produced stroke reduction in a variety of populations but has not been well tested among good risk patients with significant asymptomatic carotid stenosis who would otherwise be candidates for repair. 5,8,9,20e24 4) Repair has also improved due to patching and medical management and has been performed with lower risk than before (Table 2) . 1,2,25e28 Antiplatelet agents and statins have made repair as much as 50% safer. 26,29e32 The small long-term annual risk of ipsilateral stroke of about 0.5% in repair patients may be even smaller when BMT is optimized. 5) Current research will help guide therapy by identifying those most likely to benefit from repair in addition to BMT and those who are at high risk for repair and therefore, less likely to benefit. 7,10,11,13,26,33,34 6) Consideration should be given to a randomized trial of BMT alone versus BMT plus repair but this will likely take a decade to plan and conduct.
What is the evidence for repair (in addition to medical management)?
After a significant carotid stenosis has developed, that lesion remains a threat to the patient until it is removed. In the ACST, for example, the annual risk of stroke after repair (0.55%) was much less than the annual risk with BMT alone (1.9%). 1 Both the ACAS and ACST studies compared CEA plus BMT versus BMT alone, and both studies demonstrated a decreased risk of stroke by approximately 50% at 5 years, even though both studies were biased against repair. 1, 2 The risk of repair is front-loaded and the downside is evident within 30 days. BMT is 'pay-as e you e go' and the risks only become evident over time. The risk of BMT alone is subject to underestimation if there is loss to follow up, death of undetermined cause, small patient cohorts or crossover to repair. Both of ACAS and ACST grossly underestimated the long-term benefits of repair for some of these reasons and by curtailing follow up soon after the benefit of repair had been determined. Had patients been followed longer, the benefit of repair would likely have been greater since the annual risk of stroke after repair was much less than the annual risk with BMT alone. 3 To put it another way, any patient that lived more than a couple years experienced a benefit to carotid repair every year for the rest of their lives while every patient who did not undergo repair continued to face an excess annual threat. In addition, it is possible that contemporary BMT, not fully implemented during ACST (by conclusion of the trial 70% were on statins), would further decrease the small annual risk of stroke after repair. We will learn more about this from CREST. 35 Repair plus BMT was shown to be the better treatment in ACST, even though the study was biased against CEA. Only 91% of patients randomized to repair received it and 18% of those randomized to BMT underwent repair. Technique and perioperative management were not standardized. Had all CEA patients been on statins and antiplatelet agents and received a patch at surgery, risk would likely have been lower. 28, 29, 32 Contemporary results of CEA show improvement and are in the range of 1.5% stroke/death risk ( Table  2 ). The perioperative risk of stroke and death for CEA in asymptomatic patients in CREST were low and will serve as a benchmark. 35 CAS is a maturing procedure and has improved significantly over the past several years and will likely continue to improve as we better understand appropriate patient selection. Data available for CAS in asymptomatic patients outside of CREST comes from high risk registries. For example, among 516 asymptomatic patients with high risk anatomy for CEA, the perioperative stroke/death rate for CAS was 1.8%. 36 The ACT 1 study is continuing to enroll standard risk asymptomatic patients randomized to BMT plus CEA or CAS. In the lead in phase, the stroke/death rate for CAS was 1.3% with no ipsilateral strokes between 30 days and 1 year. 37 Alternative methods of cerebral protection, such as reversed flow, may also play a role. 38e40 Effort has been devoted to understand which patients are most likely to benefit from repair. This will decrease the number needed to treat to prevent a stroke. High risk groups are being identified, including those with; silent infarcts, certain plaque characteristics, microemboli on Transcranial Doppler (TCD), rapid plaque progression and others. 7, 10, 12, 13, 34, 41 The bottom line: BMT plus repair was much better than BMT alone, even in a level 1 study biased against repair. BMT has improved, but other things have changed as well. As long as the perioperative risk of repair remains about the same as or less than the risk of BMT alone at 2 years, it will continue to benefit good risk patients to consider repair in addition to BMT.
What is the evidence for BMT alone?
We have no level 1 data showing that BMT alone in any era has been better than BMT plus repair. We don't know if the risk of BMT alone is low enough to obviate the benefits of repair. Shouldn't we know the answer to that before we abandon the patients who could benefit from repair? The assertion that BMT has solved the problem of asymptomatic carotid stenosis comes from several recent studies; SMART, Oxford Vascular, ACSRS and studies by Spence and Abbott. 7e9, 11, 12 These studies are not adequate to determine care.
The SMART Study, an often cited source for the supremacy of BMT, followed 221 patients with questionnaires. 8 Many of these patients would not be considered for repair, since a peak systolic velocity (PSV) of only 150 cm/s was required to be included. Only 96 patients had a 70e99% stenosis, with a PSV > 210 cm/s. Stroke occurred in 2.7% over 3.6 years but 6% had CEA and 1% had CAS and deaths due to stroke were included in the general category of death (15%) and we don't know how many deaths were stroke-related. The Oxford Vascular Study reported a 0.34% ipsilateral stroke rate per year with BMT alone. 9 Another 1.8% per year developed ipsilateral transient ischemic attacks and many went on to have CEA. Other territory strokes occurred in 8.3% per year. Unspecified vascular death occurred in 7.7%. There were 101 patients with !50% stenosis followed in the study but only 32 patients had 70e99% stenosis. In another line of investigation, Spence used TCD to identify asymptomatic carotid stenosis patients (PSV ! 170 cm/s) with and without microemboli. 7 Those with microemboli had a stroke risk of 10.3% the first year and 18.5% the second year. One can only guess why all the microemboli patients were not referred for CEA after the first year. In those who did not have microemboli, the first year risk of stroke was 1.4% and the second year risk of stroke was 1.8%. Although Spence advocates against repair in this group (those remaining after the high risk microemboli patients are excluded), the cumulative 2 year risk of stroke was approximately 3.2% with contemporary BMT alone. This is only a little less than the 2 year stroke in the all-comers BMT group in the ACST (about 4%) and is more than twice as high as the perioperative risk of CEA plus BMT in the CREST Trial. 35 When other end points were included (stroke or death or CEA) in those with no microemboli, the risk was 6.5% at 2 years. Even in the lower risk, no microemboli group, the benefit of repair in addition to BMT could be significant if repair is provided at a low risk, in the range of 2% or less. In another study, Abbott did not show such a dramatic difference between those with and without microemboli on TCD. 12 The microemboli group had an annual TIA/stroke risk of 10% and in the group with no microemboli it was 7%. Both these groups would likely benefit from repair as long as it can be done with low risk. ACSRS followed 462 patients who had !60% stenosis in relationship to bulb diameter (ECST method e these could be 30% diameter reduction by NAS-CET criteria). CT scans were performed to identify those with silent cerebral infarcts. The ipsilateral annual event rate was 4.6% when infarcts were present and 2.4% when no infarcts were present. The annual risk of stroke was 3.6% with and 1% without silent infarcts. 10 The above studies have been used to extrapolate a trend and suggest a stroke rate approaching zero with modern BMT. 4 This is duly noted but is an indirect evidence of the benefits of BMT. These studies were generally compromised by a number of recurring problems; inclusion of minimal lesions, unclear endpoints, mixed groups, short-term follow up, and only small groups with bonafide carotid stenosis that would have been considered for repair. In each of the aforementioned studies, for example, duplex was used to quantify carotid stenosis. The last time that a major asymptomatic carotid study carefully analyzed degree of stenosis by angiography, was in the follow up of NASCET patients with asymptomatic contralateral carotid stenosis. 42 The stroke rate was 3.2% per year and the highest risk was in those with 75e94% stenosis (18.5% stroke at 5 years). Incidentally, 80% of the strokes were not preceded by TIA. Calls for the cessation of repair are being made on the basis of these data, without much acknowledgment of the challenges of BMT alone.
BMT is desirable and necessary and is discussed as if it was fully formed and possible to broadly implement. In fact, BMT is not simple to characterize or to produce; it is challenging to accomplish in broad populations because it is expensive, time consuming, complicated, requires vigilance and compliance and has its own side-effects and complications. 43 There are those who will not be able to quit smoking and those who cannot tolerate statins or antiplatelet agents. Not everyone will be convinced to take flax seed and grapefruit juice. Today's BMTwill be tomorrow's obsolete practice. What is the real world risk of stroke with BMT alone, especially over the long term, given that there will be noncompliance and intolerance that reduce the efficacy of the medical regimen? Compliance with a complex medical regimen will likely be higher in a study where investigators go about proving biases with impractically labor intensive practices but likely lower in the real world. Whereas in the real world, you have either had your carotid fixed or not. In addition to the disadvantages of BMT, there is a downside to lack of repair; continued annual risk of stroke in excess of the annual risk after repair, psychological effects of living with a threatening lesion, and the potential of long-term cognitive deterioration. 44e48 Drawing ridiculous conclusions from skimpy evidence, some have called for a cessation or severe limitation of carotid repair. 4, 5, 49 It is disingenuous to treat small groups of asymptomatic patients with non-lesions, to see that they remain asymptomatic with BMT and then claim victory. The old risks of repair are being compared with pseudo-natural history studies of modern BMT in patients with lesions that might never have been considered for repair. All the while, those with carotid stenosis could go on to have preventable strokes without repair under a misguided and nihilistic approach. Incidentally, what is the late follow up of medically managed patients who still harbor these lesions? We don't have any. 
Conclusion
Patients that present with stroke due to carotid stenosis, at some previous time had an asymptomatic lesion and an opportunity for repair. Repair of carotid stenosis, by CEA and in some cases CAS, in addition to BMT is currently the best way to treat most asymptomatic patients with 60e99% carotid stenosis. How well can BMT alone handle the problem? This will take a trial and 10 years. What we know now is that each time it was fairly evaluated, when repair was added to BMT, it cuts the risk in half. When repair is used judiciously in concert with BMT and performed well, it can have life-long protective effects against stroke-related death and disability for patients with asymptomatic carotid stenosis. We should continue to provide repair to good risk patients with significant asymptomatic carotid stenosis and continue to look for ways to identify which patients are most likely to benefit from repair.
Introduction
Thomas Kuhn invented the term 'paradigm shift'. This occurs when "scientists tend to work within one set of ideas about how the world is. Everything they do, be it experimental or theoretical, is informed by, and framed within, that set of ideas. However, there will be evidence that does not fit. At first, that evidence will be ignored or sabotaged. Eventually though, the anomalies will pile up so high that they simply cannot be ignored or sabotaged any longer. Then comes crisis". 50 In this debate, I will contend that 'anomalous' evidence challenges the 'one size fits all approach to treating asymptomatic carotid disease. We need a paradigm shift in thinking'. In the 1970s, surgeons were convinced that carotid endarterectomy (CEA) prevented stroke in asymptomatic patients. Their intuition was vindicated with the Asymptomatic Carotid Atherosclerosis Study (ACAS) 2 and the Asymptomatic Carotid Surgery Trial (ACST), 1 leading the American Heart Association (AHA) to conclude that CEA was "recommended in highly selected patients with high-grade asymptomatic stenoses, provided it was performed by surgeons with <3% morbidity & mortality". 17 This is generally translated to mean "CEA is appropriate in asymptomatic patients with 60e99% stenoses".
The AHA recommendation (updated in 2006 51 ) is based on the highest level of evidence; so why the debate? Unlike the symptomatic trials (which provided Level I evidence for intervention and enduring multi-disciplinary consensus), there is less agreement about managing asymptomatic patients. Notwithstanding the conservatism of some Neurologists, the only issue for many Surgeons/Interventionists is whether CEA or carotid artery stenting (CAS) is now the preferred intervention. In their world, CEA significantly reduces the risk of stroke by 50% and that (alone) is compelling enough evidence for intervening. Using Kuhn's principle, they are "working within one set of ideas about how the world is". They are also hostile to anyone who suggests that their reasoning might be flawed.
The AHA recommendation includes the phrase "highlyselected". Unfortunately, no clarification was forthcoming about what this meant and physicians have to interpret this for themselves (in reality it is ignored). However, defining who benefits most (and least) from intervention is crucial to this debate and brings us to those anomalies that challenge current guidelines and support a paradigm shift in thinking. These are chronologically listed in Table 3 and the most important will be debated after reviewing how critics responded to them.
Physicians have (not unreasonably) adopted the role of patient advocate should anyone suggest that intervention might be unnecessary; (i) "you would never send someone home with occlusive disease of the left main coronary artery; why then would you send home a patient with a critical stenosis of a dominant hemisphere internal carotid with a 95% stenosis?", 53 (ii) "it is politically untenable to deny women, and not men prophylactic CEA" 54 and (iii) "but what about the patient? He understands that his brain is threatened by a severe carotid stenosis, no matter what the overall percentage of this threat actually is. They should also understand that denying surgery equates to being exposed life long to a cumulative risk of a cerebrovascular event". 55 Vox populi comments include; (i) "as long as 80% of strokes are not preceded by a TIA, I will treat asymptomatic patients", (ii) "women live longer, therefore it is unreasonable to withhold CEA/CAS", (iii) "patients are not always compliant with taking medications. It is safer to offer CEA" and (iv) "surgeons need to focus on the welfare of the individual and not the population". Next comes media hype; a classic example being the 1994 New York Times commentary (following the ACAS Alert) which stated that "50% fewer strokes will occur if asymptomatic individuals with >60% stenoses are submitted to surgery". 57 This, I suspect, is a commonly quoted statistic when risk:benefit is discussed with patients. It is also a good example of being 'economical with the actualité'.
Methodological criticisms include; "as experts in this domain, we should rely on strong, though not necessarily fully evidence based arguments and draw our own conclusions about the case of our specific patient", 55 (ii) "subgroup analyses can be ignored as the trials were never powered to make these conclusions" and (iii) "these data are from very old studies and have little relevance in today's world, especially now CAS is available." Realities of professional life (conceded 'off the record') include; "if I do not operate on this patient, someone else will and I will lose income". Finally, if all else fails, why not resort to censure; (i) "why should we, who work in a first-world health service, pay any attention to someone working in a third-world system" (2005 Charing Cross Symposium) and (ii) "what is more paradoxical is the attitude of some who become progressive opinion leaders, despite the fact that the message they deliver is a deliberate and insistent nonoperating pleading in the case of asymptomatic disease.
Using mostly statistical or economic arguments, rather than medical evidence, they aim to demonstrate that prophylactic CEA, even in being probably the safest approach in skilled hands, was not medically justified, nor cost-effective for public savings". 56 Ouch!.
The preceding counterarguments to Table 3 0 s anomalies mask a growing crisis, primarily because some are now too important to remain ignored. Firstly; ACAS/ACST showed that almost 90% of medically treated patients were never destined to suffer a stroke within 5 years. 1, 2 That should, of course, make me winner in this debate (read the title), but I see you remain unconvinced. Second, is the uncomfortable observation that even if you could treat everyone fulfilling ACAS criteria with a 2.3% procedural risk; 95% of strokes will still happen. 14, 56 This is because CEA/CAS cannot prevent the 70% of strokes unrelated to carotid disease, while two-thirds of carotid origin strokes will not have significant stenoses and 15e20% will present with a TIA. That leaves about 8e10 patients whose strokes will be attributable to significant, asymptomatic carotid disease in whom to target interventions. 58 However, CEA reduces stroke by 50%, 1,2 so that only 5 strokes (at most) will be prevented. Consider that the next time someone justifies 'mass intervention' because '80% of strokes are unheralded'.
If you still believe that CEA/CAS confers benefit in the majority of asymptomatic patients, have you considered the logistics of finding and treating them? With a population of 1.3 million, let us assume that Peter Schneider and his colleagues can somehow identify the 1% of Hawaiians (13,000) with an asymptomatic 60e99% stenosis (this would normally take years). Assuming theatres/catheter suites work every week-day (260 pa) and 10 CEA/CAS procedures are performed somewhere on the island on every one of these days (i.e., 2600 interventions in asymptomatic patients per year; quite a big ask), it would take five years Table 3 'Anomalies' regarding a 'one size fits all' policy of offering CEA (or CAS) to 'standard risk' patients with 60e99% asymptomatic carotid stenoses.
1991
ACAS: 40% of surgeon applicants rejected, raising questions about generalisability 67 1995 ACAS: with a 2.3% procedural risk, CEA prevents only 59 strokes at 5 years per 1000 CEAs 2 ACAS: with procedural risk included, CEA conferred no benefit in women 2 ACAS: no relationship between stenosis severity/bilateral disease and late stroke risk 2 Even if you could treat every patient, 95% of all strokes in the community will still occur 56 1996 Hertzer concedes that the annual risk of stroke in ACAS was much lower than expected 68 ACAS: even with the procedural risk excluded, CEA still conferred no benefit in women 69 First editorial to question whether ACAS results warrant a tenfold increase in CEA numbers 70 1997 Canadian Neurologists & Stroke Physicians recommend against CEA & screening 71 2000 ACAS: CEA does not confer significant benefit in patients with a contralateral occlusion 72 55% of late strokes are cardioembolic or lacunar; ie majority are not due to ICA embolism 73 2001 7/10 US States report procedural risks >3% following CEA 74 Using ACST entry criteria; the average procedural risk after CEA in 10 US states was 5.9% 74 2002 ACAS; had their data been analysed at 4 years, CEA would have conferred no benefit 70 2003 European Stroke Initiative suggests that medical treatment is now probably the best option 75 Editorial suggests that the randomized trials should be repeated 76 2004 ACST: CEA conferred no benefit in patients aged >75 years 1 ACST: no association between stenosis severity/bilateral disease and late stroke risk 1 ACST: if procedural risk included, CEA conferred no significant benefit in women 60 ACST: most of the benefit was seen in patients with a pre-randomisation cholesterol >6.5. 1 Using ACST inclusion criteria, the average procedural risk after CEA in 10 US states was 5.4% 78 Meta-analysis of 46 contemporary surgical studies found mortality Â 8 higher and death/stroke Â 3 higher compared with outcomes in ACAS 77 2005 92% of all carotid revascularisations in USA are now performed in asymptomatic patients 25 2007 US Task Force recommends against screening (benefits too low and do not outweigh risks) 59 Annual risk of stroke in medically treated patients has been decreasing over the last 20 years 6 2008 Published evidence that high statin therapy stabilises asymptomatic carotid plaques 33, 34 Even with 15 yr follow up it is never cost effective to offer CEA to females, irrespective of age 79 NEJM poll: 50% of respondents worldwide would treat asymptomatic patients conservatively 63 Editorial suggests that it may be time to stop intervening in asymptomatic patients 49 If the procedural risk of death/disabling stroke exceeded 2.1%, or if the annual rate of fatal/disabling stroke was <1.09%, CEA/CAS will not confer any long term benefit 62 2009 Systematic Review; non-interventional therapy now safer than CEA/CAS (attributed to improvements in medical therapy) and is 3e8 times more cost-effective 4 94% of CEA/CAS procedures in USA are ultimately unnecessary, costing $2.1 billion pa 14, 61 Evidence of sustained decline in annual stroke risk in medically treated patients in ACAS & ACST 14 2010 Evidence that high statin therapy significantly reduces spontaneous embolisation 7 Meta-analysis of 3 recent studies (1635 patients); ipsilateral stroke risk now only 0.5% per year 9 More calls for randomized trials comparing CEA with CAS to include a third medical limb 14, 52, 65, 66 to clear the backlog. During this time, some will suffer a stroke whilst awaiting treatment and more 'at-risk' populations will emerge. In reality, a policy of operating upon as many asymptomatic patients as possible will only prevent about 1% of all strokes. But 'mass interventions' consume resources. Using ACAS data, performing CEA/CAS with a 2.3% risk prevents 59 ipsilateral strokes/1000 procedures at 5 years 14 (indisputable fact). The number of 'any' strokes prevented Z 51. In 2005, 122,986 revascularisations were undertaken in asymptomatic patients in the USA 25 and simple maths (59 Â 122.986) show that only 7256 patients will have ipsilateral strokes prevented. This also means that in 2005, 115,730 (94%) underwent an ultimately unnecessary intervention. Using US financial data, 25 unnecessary interventions cost US Health Providers $2.1 billion each year. 14, 61 That is surely unsustainable.
Ah, but you probably feel that my debate has focussed excessively on logistics, 'cold' statistics and expenditure and not enough upon the individual patient? No, I would not allow that. Notwithstanding the 30þ anomalies detailed in Table 3 , the single most important reason why a paradigm shift in thinking is unavoidable is because the most venerated of 'sacred cows' is under threat. That is the assumption that the annual rate of stroke in medically treated patients remains about 2%. If the annual risk has decreased since ACAS/ACST published, many of the risk:benefit calculations become vulnerable to challenge. If the annual risk falls to 1%, it is unlikely that CEA/CAS could ever confer significant benefit. 62 What would you think if I suggested that the annual risk of ipsilateral stroke may now be as low as 0.5e0.7%?
Abbott was one of the first to observe that the annual risk of stroke in medically treated patients has declined significantly over the last 20 years 4,6,49 and her latest metaanalysis concludes that non-interventional therapy is the safer option, whilst also being more cost-effective. 4 A second (smaller) meta-analysis published in 2010 included natural history data from three studies recruiting after 2000 and found that the average annual risk of ipsilateral stroke in 1635 medically treated patients was 0.5%. 9 Abbott (and others) have attributed this decline in stroke risk to improvements in BMT, especially through the use of high dose statins. 4, 7, 14, 20, 33, 34 Not surprisingly, this has elicited the inevitable counter-argument 64 (recognise a trend?), primarily because some studies in Abbott's meta-analysis included patients with 50e99% as opposed to 60e99% stenoses. 64 However, neither ACAS/ACST, nor a raft of natural history studies has consistently shown that late stroke is associated with stenosis severity. 1, 2, 14 Moreover, an alternative interpretation of data from ACAS and ACST suggests that they (too) have encountered year on year reductions in stroke risk. They just haven't acknowledged it yet.
ACAS published five-year data in 1995, ACST in 2004 and then released 6e10 year data during 2008/2009, 1,2,14 giving observers three sequential five-year periods for comparison. In 1995, ACAS reported a five-year risk of 'any' stroke of 17.5% (i.e., 3.5% pa) in medically treated patients. The risk of 'any' stroke in years 1e5 of ACST fell to 11.8% (i.e., 2.4% pa), while in the second five-year period of study (i.e., years 6e10 of ACST), the risk of 'any stroke' decreased to 7.2% (i.e., 1.4% pa). In 1995, ACAS reported a five-year risk of 'ipsilateral' stroke of 11.0% (i.e., 2.2% pa) in medically treated patients. By 2004, the five-year risk of 'ipsilateral' stroke in ACST had fallen to 5.3% (i.e., 1.1% pa), while in the second five-year period (i.e., years 6e10 of ACST), the risk of 'ipsilateral stroke' decreased to 3.6% (i.e., 0.7% pa). This means that the average annual risk of 'any' stroke has declined by 60% from 3.5% to 1.4% in 15 years since ACAS published, while the annual average risk of 'ipsilateral' stroke has declined by 67% from 2.2% to 0.7%. This, in conjunction with Abbott's meta-analysis, suggests that there has been a significant, sustained decrease in the annual risk of stroke.
So who will win this debate? The paradox is that I can neither win nor lose. Until influential bodies (i.e., the AHA) consider the implications of a declining stroke risk and revise their recommendation (i.e., triggering a paradigm shift in thinking), nothing will change. This is because the AHA wields the greatest influence over practice worldwide and Surgeons/Interventionists will continue to offer 'mass interventions', not least to minimise medico-legal censure. To many observers, 4, 14, 52, 65, 66 (including the Principle Investigator of CREST 66 ) we need to undertake an adequately powered randomized trial which includes treatment arms for CEA, CAS and BMT. This should make it possible to test algorithms for identifying 'high risk for stroke' subgroups (e.g., TCD embolisation, silent infarction on CT, incomplete circle of Willis, computerised plaque morphology, biomarkers). Surely we must focus resources towards intervening in only a very small cohort of 'high risk for stroke' patients?
Conversely, it is also true that I cannot lose this debate. It is indisputable that the vast majority of patients with asymptomatic carotid disease will never suffer a stroke, only 1% of strokes will be prevented through a mass campaign of uncritical intervention, 94% of interventions in asymptomatic patients are ultimately unnecessary and the annual risk of stroke is now very much lower than it was in 1995. How else could you interpret the data? Unless, of course, you remain distracted by other conflicts of interest.
